HEALTH OF WOMAN. 2016.5(111):137–142; doi 10.15574/HW.2016.111.137 
 

Modern determinants of endometrium hyperplastic processes pathogenesis 
 

Benyuk V. O., Goncharenko V. M., Nykoniuk T. R.

A.A. Bogomolets National Medical University, Kiev

The objective: to еxplore the relationship between the activity of endometrial proliferation and the state of the local immune response in the uterus in the conditions berprestasi process.

Patients and methods. Examined 228 women of reproductive and perimenopausal age with endometrial pathology using ultrasound and then performing hysteroresectoscopy. Determination of the concentrations of the cytokines IL-1, IL-2, IL-6 and TNF was performed by solid phase ELISA.

Results. Found a trend that confirms the loss of sensitivity to hormones at the stage of malignancy of the endometrium and can be used as diagnostic determinants in determining the nature of intrauterine pathology and criterion of the effectiveness of conservative therapy.

Conclusion. Improving etiopatogenetice approach to the therapy of hyperplastic proce.sses of endometrium with determination of receptor phenotype of the endometrium is a research direction in modern gynecology, which will help to improve the results of treatment and prevention of intrauterine pathology.

Key words: endometrial hyperplasia,the receptors for progesterone and estrogen, immunohistochemical method.

REFERENCES

1. Zaporozhan VN, Tatarchuk TF, Dubinina VG, Cossey N. 2012. Current diagnosis and treatment of hyperplastic processes of endometrium. Reproductive endocrinology. 1(3):5-12.

2. Benyuk VA. 2013. Intrauterine pathology. 6(42):206.

3. Dubinina VG. 2007. Forecasting and early diagnostics of tumor diseases of the endometrium. Thesis for the degree of doctor of medical Sciences. Kyiv.

4. Benyuk VA, Kurochka VV, Winarski JM, Goncharenko VM. 2011. Modern aspects of diagnosis of endometrial hyperplastic processes in women of reproductive age. Tauride medical and biological Bulletin. 15(2):20.

5. Van Bogaert L-J. 1988. Clinicopathologic findings in endometrial polyps. Obstet. Gynecol. 71:771–773. PMid:3357665

6. Sherman ME, Mazur MT, Kurman RJ. 2002. Benign diseases of the endometrium. Blaustein’s pathology of the female genital tract:421–466.

7. Dubinina VG, Rybin AI. 2002. Immune-endocrine relationship in women of reproductive age with different types of transformation of the endometrium. Bucovin. med. VSN. 6:214-219.

8. Vasyl Beniuk A, Yaroslav Vyniarskyi M, Sergiy Bashynskyi M and Rostyslav Bubnov V. 2014. Assessment of endometrial receptor systems for PPPM approach for endometrial hyperplasia in reproductive age women. EPMA Journal 5 (Suppl-1): A40. http://www.epmajournal.com/content/5/S1/A39/abstract

9. Benyuk VA, Kurochka VV, Winarski JM, Goncharenko VM. 2009. Diagnostic algorithm intrauterine pathology with the use of hysteroscopy in women of reproductive age. Women's Health. 6(42):54-56.

10. Kiselev VI, Sidorova IS, Unanyan AP, Muisek EL. 2011. Hyperplastic processes of the female reproductive system: theory and practice:468.

11. Tkachenko LV, Sviridov NI, Isaeva LV, Bogatyreva LN. 2011. Combined method of treatment of recurrent endometrial hyperplastic processes in women with metabolic syndrome. Ural medical journal 4(82):72-75.

12. Chepik OF. Morphogenesis of endometrial hyperplastic processes. Pract. oncol. 5(1):9-15.

13. Chernukha GE. 2009. Endometrial Hyperplasia: prospects for development problems. Akusha. and gin. 4:11-15.

14. Chissov VI, Starinsky VV, Petrova GV. 2008. Malignant neoplasms in Russia in 2006 (Morbidity and mortality). M.

15. Sheshukova NA, Makarov IO, Fomina MN. 2011. Hyperplastic processes of the endometrium: etiology, pathogenesis, clinic, diagnostics, treatment. Akusha. and gin. 4:16-21.

16. Romanovskii OY. 2004. Hyperplastic processes of the endometrium in the reproductive period (literature review). Gynecology 6(6):14.

17. Friberg E et al. 2007. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 50(7):1365-1374. http://dx.doi.org/10.1007/s00125-007-0681-5; PMid:17476474

18. Gallagher EJ, LeRoith D. 2011. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann. N Y Acad. Sci. 1243:54-68. http://dx.doi.org/10.1111/j.1749-6632.2011.06285.x; PMid:22211893

19. Runowicz CD et al. 2011. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am. J. Obstet. Gynecol. 205:535.e1- e5. http://dx.doi.org/10.1016/j.ajog.2011.06.067; PMid:21872200

20. Rizner TL. 2013. Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Mol. Cell. Endocrinol. 381:124-139. http://dx.doi.org/10.1016/j.mce.2013.07.026; PMid:23911898

21. Zhang ZH et al. 2013. The Role of Preexisting Diabetes Mellitus on Incidence and Mortality of Endometrial Cancer: A Meta-Analysis of Prospective Cohort Studies. Int. J. Gynecol. Cancer. 23(2):294-303. http://dx.doi.org/10.1097/igc.0b013e31827b8430